Research Analysts Issue Forecasts for Sanofi FY2024 Earnings

Sanofi (NASDAQ:SNY) – Equities research analysts at Leerink Partnrs issued their FY2024 EPS estimates for shares of Sanofi in a research report issued to clients and investors on Monday, January 27th. Leerink Partnrs analyst D. Risinger expects that the company will post earnings of $3.77 per share for the year. The consensus estimate for Sanofi’s current full-year earnings is $3.82 per share. Leerink Partnrs also issued estimates for Sanofi’s Q4 2024 earnings at $0.74 EPS, Q1 2025 earnings at $0.75 EPS, Q2 2025 earnings at $0.84 EPS, FY2025 earnings at $4.06 EPS, FY2026 earnings at $4.57 EPS, FY2027 earnings at $4.76 EPS and FY2028 earnings at $5.39 EPS.

Several other equities analysts have also commented on SNY. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $60.00.

Sanofi Trading Up 3.8 %

Shares of SNY opened at $54.15 on Thursday. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The stock has a fifty day moving average of $49.12 and a two-hundred day moving average of $52.24. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The company has a market capitalization of $137.42 billion, a PE ratio of 27.63, a price-to-earnings-growth ratio of 1.19 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 9.96% and a return on equity of 27.45%.

Institutional Investors Weigh In On Sanofi

Several large investors have recently made changes to their positions in the business. Jennison Associates LLC boosted its position in Sanofi by 938.0% in the 3rd quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock valued at $109,753,000 after buying an additional 1,720,972 shares during the last quarter. Thrivent Financial for Lutherans boosted its holdings in Sanofi by 28,890.2% in the third quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock valued at $82,366,000 after purchasing an additional 1,424,289 shares during the last quarter. DAVENPORT & Co LLC boosted its holdings in Sanofi by 40.7% in the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock valued at $110,715,000 after purchasing an additional 664,455 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Sanofi by 20.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after purchasing an additional 399,301 shares in the last quarter. Finally, Franklin Resources Inc. increased its holdings in Sanofi by 13.1% during the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after purchasing an additional 395,744 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.